Profile data is unavailable for this security.
About the company
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
- Revenue in USD (TTM)12.26m
- Net income in USD-46.15m
- Incorporated2006
- Employees82.00
- LocationCorMedix Inc300 Connell Drive, Suite 4200BERKELEY HEIGHTS 07922United StatesUSA
- Phone+1 (908) 517-9500
- Fax+1 (302) 636-5454
- Websitehttps://cormedix.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SIGA Technologies Inc | 173.73m | 85.71m | 406.29m | 45.00 | 4.80 | 2.40 | 4.71 | 2.34 | 1.19 | 1.19 | 2.42 | 2.37 | 0.9823 | 0.5034 | 17.25 | 3,860,698.00 | 48.46 | 22.34 | 57.01 | 27.56 | 81.60 | 88.65 | 49.33 | 41.14 | 5.32 | -- | 0.00 | 29.51 | 26.31 | -21.75 | 100.76 | -30.57 | -26.67 | -- |
| SNDL Inc | 633.80m | -76.82m | 414.18m | 2.52k | -- | 0.4927 | -- | 0.6535 | -0.2931 | -0.2931 | 2.41 | 3.17 | 0.6062 | 4.98 | 36.38 | 251,909.10 | -7.61 | -24.44 | -8.22 | -27.94 | 25.69 | 22.49 | -12.55 | -62.17 | 4.16 | -- | 0.114 | -- | 27.63 | -- | 49.83 | -- | -- | -- |
| Zevra Therapeutics Inc | 24.79m | -84.93m | 432.35m | 65.00 | -- | 6.18 | -- | 17.44 | -1.96 | -1.96 | 0.5825 | 1.31 | 0.150 | -- | 2.80 | 381,323.10 | -51.39 | -32.11 | -61.91 | -39.89 | 53.72 | -- | -342.63 | -128.42 | -- | -25.93 | 0.4578 | -- | 170.26 | -- | -72.00 | -- | 69.75 | -- |
| Theravance Biopharma Inc | 64.38m | -56.42m | 468.63m | 99.00 | -- | 2.69 | -- | 7.28 | -1.15 | -1.15 | 1.32 | 3.55 | 0.1749 | -- | 3.59 | 663,721.60 | -15.33 | -34.51 | -16.61 | -40.08 | -- | -- | -87.63 | -254.51 | -- | -- | 0.1473 | -- | 12.12 | -2.59 | -2.22 | -- | -36.34 | -- |
| Eyepoint Pharmaceuticals Inc | 43.27m | -130.87m | 490.04m | 165.00 | -- | 1.45 | -- | 11.32 | -2.31 | -2.31 | 0.7687 | 4.93 | 0.1119 | 1.20 | 61.29 | 262,260.60 | -33.83 | -35.88 | -39.58 | -42.05 | 91.42 | 84.82 | -302.43 | -201.78 | 7.77 | -- | 0.00 | -- | -5.97 | 16.27 | -84.86 | -- | 80.24 | -- |
| Elite Pharmaceuticals Inc | 70.00m | -17.99m | 513.31m | 64.00 | -- | 14.08 | -- | 7.33 | -0.0167 | -0.0167 | 0.0659 | 0.0341 | 0.8461 | 2.27 | 4.06 | 1,093,699.00 | -21.74 | 19.07 | -27.33 | 24.29 | 44.16 | 46.63 | -25.70 | 20.77 | 1.90 | 0.4235 | 0.1988 | 0.00 | 65.79 | 49.55 | 464.56 | -- | 111.50 | -- |
| Precigen Inc | 3.96m | -139.56m | 544.74m | 202.00 | -- | 9.84 | -- | 137.46 | -0.5479 | -0.5479 | 0.0154 | 0.1891 | 0.0289 | -- | 5.40 | 19,618.81 | -101.81 | -31.50 | -126.84 | -38.63 | -12.44 | 44.00 | -3,521.68 | -232.32 | -- | -- | 0.00 | -- | -76.87 | -47.16 | -20.22 | -- | -48.30 | -- |
| Sinovac Biotech Ltd | 429.20m | -130.73m | 639.90m | 3.04k | -- | -- | -- | 1.49 | -1.31 | -1.31 | 4.31 | 86.81 | 0.0322 | 0.2019 | 1.08 | 141,325.00 | -2.23 | 36.14 | -3.30 | 58.37 | 92.09 | 90.77 | -69.19 | 65.87 | 11.24 | -- | 0.0262 | -- | -69.97 | 14.31 | -198.16 | -- | 91.80 | -- |
| CorMedix Inc | 12.26m | -46.15m | 649.85m | 82.00 | -- | 10.56 | -- | 53.00 | -0.8011 | -0.8011 | 0.212 | 1.01 | 0.1451 | -- | -- | 149,539.50 | -54.61 | -54.84 | -64.60 | -62.32 | 83.57 | 6.18 | -376.35 | -18,323.42 | 3.60 | -- | 0.00 | -- | -100.00 | -- | -56.02 | -- | 46.27 | -- |
| Tilray Brands Inc | 829.22m | -248.96m | 650.45m | 2.65k | -- | 0.1849 | -- | 0.7844 | -0.3062 | -0.3062 | 1.01 | 3.75 | 0.1946 | 2.22 | 8.16 | 312,911.70 | -5.64 | -- | -6.13 | -- | 30.47 | -- | -28.98 | -- | 1.58 | -0.8346 | 0.0924 | -- | 25.80 | -- | 83.14 | -- | -- | -- |
| Xeris Biopharma Holdings Inc | 203.07m | -54.84m | 652.71m | 394.00 | -- | -- | -- | 3.21 | -0.3761 | -0.3761 | 1.38 | -0.1982 | 0.629 | 0.8466 | 5.10 | 515,406.10 | -16.99 | -31.61 | -24.37 | -42.28 | 81.86 | 79.76 | -27.00 | -77.77 | 1.19 | -1.34 | 1.15 | -- | 23.89 | 136.89 | 11.92 | -- | -4.75 | -- |
| Avadel Pharmaceuticals PLC (ADR) | 169.12m | -48.83m | 764.34m | 188.00 | -- | 10.34 | -- | 4.52 | -0.5215 | -0.5215 | 1.78 | 0.7651 | 1.03 | 0.996 | 7.32 | 899,558.50 | -29.69 | -42.00 | -40.15 | -50.53 | 90.97 | -- | -28.87 | -194.15 | 2.33 | -3.92 | 0.00 | -- | 504.79 | 23.35 | 69.53 | -- | -- | -- |
| Evolus Inc | 266.27m | -50.42m | 863.51m | 332.00 | -- | 156.16 | -- | 3.24 | -0.8146 | -0.8146 | 4.29 | 0.087 | 1.26 | 7.25 | 6.81 | 802,030.10 | -23.92 | -37.04 | -32.50 | -57.14 | 68.46 | 65.19 | -18.94 | -51.26 | 2.21 | -1.76 | 0.9565 | -- | 31.76 | 50.12 | 18.26 | -- | 1.10 | -- |
| Harrow Inc | 169.14m | -33.41m | 868.29m | 315.00 | -- | 14.98 | -- | 5.13 | -0.9408 | -0.9408 | 4.76 | 1.63 | 0.5305 | 4.86 | 4.69 | 536,946.10 | -10.48 | -10.86 | -12.74 | -12.71 | 72.56 | 70.75 | -19.75 | -15.35 | 1.44 | -0.3529 | 0.7635 | -- | 46.95 | 25.77 | -73.30 | -- | 143.88 | -- |
| Collegium Pharmaceutical Inc | 631.45m | 69.19m | 910.25m | 357.00 | 15.67 | 3.97 | 3.82 | 1.44 | 1.84 | 1.84 | 15.55 | 7.28 | 0.4499 | 7.49 | 3.09 | 1,768,765.00 | 4.93 | 4.11 | 7.52 | 6.64 | 59.76 | 55.50 | 10.96 | 8.48 | 0.8767 | 3.24 | 0.7884 | 0.00 | 11.41 | 16.31 | 43.68 | -- | -23.82 | -- |
Data as of Mar 10 2025. Currency figures normalised to CorMedix Inc's reporting currency: US Dollar USD
26.35%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2024 | 4.20m | 6.92% |
| The Vanguard Group, Inc.as of 31 Dec 2024 | 3.25m | 5.36% |
| Elliott Investment Management LPas of 31 Dec 2024 | 2.87m | 4.73% |
| SSgA Funds Management, Inc.as of 31 Dec 2024 | 1.45m | 2.40% |
| Geode Capital Management LLCas of 31 Dec 2024 | 1.39m | 2.30% |
| First Turn Management LLCas of 31 Dec 2024 | 1.02m | 1.68% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2024 | 511.57k | 0.84% |
| J. Goldman & Co. LPas of 31 Dec 2024 | 457.32k | 0.75% |
| D. E. Shaw & Co. LPas of 31 Dec 2024 | 446.41k | 0.74% |
| UBS Securities LLCas of 31 Dec 2024 | 379.27k | 0.63% |
More ▼
Data from 31 Dec 2024 - 31 Dec 2024Source: FactSet Research Systems Inc.
